Evidence map›Paper›PMID 15664230›Full record

ReviewLancet (London, England)

Chronic kidney disease: the global challenge.

A Meguid El Nahas, Aminu K Bello

3 registry-linked trialsAbstract readReview
PubMed Publisher
In one paragraph

Review in Lancet (London, England). The graph could read no effect estimate from its abstract, so it casts no vote on the map. It reports registered trial NCT01847313. Cited by 407 papers, 14 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
407citing papers in PubMed, 14 pooled it
26.7field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT01847313 phase3completed

Phase 3 Study of the Effect of Glucagon-like-peptide 1 (GLP-1) Receptor Agonism on Renal Outcomes in Humans With Diabetic Kidney Disease

Ran2013Enrolled20Registered outcomes6Posted comparisons0ConditionsDiabetic Kidney DiseaseArmsliraglutide
PMID 20622169PMID 20002084PMID 22691169PMID 21744074PMID 18487229PMID 19238145PMID 19585513PMID 17167242PMID 23173142PMID 14675042PMID 16177002PMID 16231067other papers from this trial
Open the trial in the graph
NCT02829450 unknown statusnot on this map

Home-based Ultrafiltration for Congestive Heart Failure: Impact on Survival, Hospitalizations Rate, Quality of Life, Peritoneal Membrane Characteristics and Residual Renal Function With Different Treatment Modes

TypeobservationalSponsorSoroka University Medical CenterRan2015 to 2020Enrolled40ConditionsChronic Kidney Disease, Congestive Heart FailureArmsperitoneal ultrafiltration
NCT03487861 unknown statusnot on this map

Development of a Diagnostic Kit for Urinary Transglutaminase 2 as a Biomarker for Kidney Allograft Fibrosis

TypeobservationalSponsorAsan Medical CenterRan2017 to 2020Enrolled1,000ConditionsKidney Allograft Fibrosis, Kidney Transplant Failure and RejectionArmsobservational(urinary biomarker for kidney allograft fibrosis)
3 · Its place in the literature

Who cites it

407 citing papers in PubMed, 14 syntheses or guidelines pooled it, 1,188 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Pooled it
  9. Pooled it
  10. Pooled it
  11. Pooled it
  12. Guideline
  13. Guideline
  14. Pooled it
  15. Sex differences in endothelial function in chronic kidney disease.American journal of physiology. Renal physiology · 2020
    Trial
  16. Trial
  17. Trial
  18. Trial
  19. Article
  20. Observational

347 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 2 institutions in 1 country.

A Meguid El NahasSheffield Kidney Institute, Sheffield Teaching Hospital NHS Foundation Trust, Northern General Hospital Campus, University of Sheffield, Sheffield S5 7AU, UK. el-nahas@sheffield.ac.uk
Aminu K Bello
Northern General Hospital · GBSheffield Kidney Institute · GB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The worldwide rise in the number of patients with chronic kidney disease (CKD) and consequent end-stage renal failure necessitating renal replacement therapy is threatening to reach epidemic proportions over the next decade, and only a small number of countries have robust economies able to meet the challenges posed. A change in global approach to CKD from treatment of end-stage renal disease (ESRD) to much more aggressive primary and secondary prevention is therefore imperative. In this Seminar, we examine the epidemiology of CKD worldwide, with emphasis on early detection and prevention, and the feasibility of methods for detection and primary prevention of CKD. We also review the risk factors and markers of progressive CKD. We explore current understanding of the mechanisms underlying renal scarring leading to ESRD to inform on current and future interventions as well as evidence relating to interventions to slow the progression of CKD. Finally, we make strategic recommendations based on future research to stem the worldwide growth of CKD. Consideration is given to health economics. A global and concerted approach to CKD must be adopted in both more and less developed countries to avoid a major catastrophe.

Indexed as

Kidney DiseasesChronic DiseaseCicatrixHumansKidneyKidney Failure, ChronicRisk Factors

Identifiers

PMID15664230
OpenAlexW2143795731

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.